ABs'rltcT: As part of the Reproductive Control Methods Project. the USDA National Wildlife Research Center (N WRC) has developed multiple non-lethal contraceptive tools to control population of over-abundant wildlife species. Working in conjunction with Dr. U. P. l'alwar of the 'hilwar Research Institute in India, scientists at NWRC have shown that a recombinant lbrm ofUnRI I peptide has successfully contracepted swine. Feral swine not only pose a significant agricultural issue due to over-population: they act as a reservoir for Bruce//a sujs, a threat to domestic livestock and humans. The Bruce//a ahortus R1151 (Rough Bruce//a) vaccine, developed for bovine brucellosis and licensed by the USDA Animal Plant Health Inspection Service, has shown protection fbr some swine and is also effective against Bruce//a suEs infection and other antigens. There is currently no approved vaccine fix swine brucellosis (feral or domestic) in the United States. Past studies performed at The Ohio State University show that Bruce/la suis vaccination appears to protect against abortion and colonization in pigs after a virulent challenge.
INTRODUCTION
Drs. G. P. TaIwar and J. C. Gupta of the Talwar Research Foundation in India have engineered a unique recombinant form of GnRH. The genetic sequence encodes for S GnRH B-cell eptitopes interspersed with 4 immunogenic, promiscuous T-cell epitopes (Guptaetal. 2004) . The combination of T-cell and B-cell epitopes is significant, as it causes the production of long-lasting lgG antibodies (Miller et al. 2006) . All of the 4 T-cell epitopes are of diverse genetic disease origin, which allows for enhanced immunogenicity (Figure 1 ). The extracted and purified recombinant multimeric protein (rmGnRH) produced from Escherichia co/i has a molecular weight between 16 and 18 kDa (Gupta et al. 2004) . This protein produces a significant immune response in swine with a single vaccina-
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Protein Sequence tion (Miller et al. 2006) . The recombinant protein's unique design is highly foreign to the host immune system, and it elicits a sufficiently strong immune response to induce immunocontraception. Gupta et al. (2004) inserted the multimeric GnRH gene sequence into an E. co/i expression vector pRSET that is commercially available from Invitrogen (Carlsbad, CA) (Figure 2 ). This unique plasmid encodes for resistance to ampicillin. The antibiotic sequence applies selection pressure resistance and allows for positive transformant growth in media containing this antibiotic. There- Wr Table 1 . Comparison of the single and dual injections of the rmGnRH vaccine (Miller et al. 2006) .
Treatment N Progesterone Positive Bred Pregnant
Taiwar one injection (750 pg)
Taiwar two injections (500-500 pg)
fore, those cells that do not receive the antibiotic resistance gene from the plasmid do not grow. Those bacteria that do receive the plasmid allow it to begin self-replication, translation of the sequences, and expression of the encoded multimeric GnRl-1 protein. Specific E. co/i strains, such as BL2 I (DES)pLysS, are engineered to over-express recombinant protein for an overall increase in protein yield. Scale-up production of this low-cost recombinant protein produced from an over-expression E. co/i strain could allow for wide-scale field use and oral delivery of contraceptive vaccine.
Dual Vaccine
As the number of feral swine (Sus scrofa) continues to grow, so does the spread of B. suis. Not only do the overabundant feral swine affect crop agriculture, B. suis infection in feral swine creates the potential for transmission incidence into food animal populations (Stoffregen et al. 2007 ). Vaccination to B.s uis in swine has been attempted using RBS I. A positive response was seen, although subsequent, more controlled studies failed to confirm these initial reports (Stoffregen et al. 2007) .
Specific bacterial strains, non-infectious to the host organism but sufficiently immunogenic to the immune system, can serve as vectors for heterologous recombinant protein expression and induction of a humeral immune response to the recombinant protein or antigen. Oral vaccination utilizing attenuated bacterial strains is common, with use of RB5 1 intended to vaccinate cattle and bison against Bruce/la abortus (Vemulapalli et al. 2000) . In addition, attenuated Salmonella have been utilized in vaccinating mice against tetanus (Fairweather et al. 1990 ). Certain strains of Bruce//a have recently been studied as potential candidates for a Bruce//a vaccine for domestic and feral swine. For example, strain 353-1 from the National Animal Disease Center in Ames, Iowa is a naturally occurring rough mutant of Bruce/la that shows potential as a viable oral vaccination tool (Stoifregan et al. 2007) . The humeral and cell-mediated immune response to 353-1 exposure elicited antibody production that provided systemic protection of swine B. suis post challenge.
Because strain 353-1 produces a humeral immune response and allows for protection post challenge, subcloning of the Talwar recombinant sequence from the E. co/i compatible plasmid, pRSET, into a Bruce//a-compatible plasmid would permit transformation into B. suis strain 353-1 . Antibodies made to the expressed rmGnRH protein will bind endogenous circulating GnRH. The antibody binding of endogenous GnRH produced by the hypothalamus decreases the normal stimulatory activity of GnRH on the anterior pituitary. This results in decreased LH and FSI-I secretion leading to decreased fertility.
METHODS
The plasmid construct was successfully transformed into E. co/i strain BL2I(DE3)pLysS, a strain engineered as a high-protein expression model. The new recombinant bacterial strain confers resistance to ampicillin, confirming a successful transformation. The expressed proteins, mainly localized in the cytosol as insoluble inclusion bodies, are purified by Ni+-NTA chromatography (Gupta et al. 2004 ). Total protein yield will range depending on the bacterial strain.
Contraceptive efficacy utilizing rmGnRH was investigated at Pennsylvania State University (PSU) in 2005 in reproductively mature gilts. The rmGnRH combined with the NWRC adjuvant AdjuVac produced a significant antibody response with a single injection (Miller et al. 2006) . Contraception of 3 of 5 guts was observed: an impressive immunogenic response for a small recombinant (16) (17) (18) kDa) protein (Table I ). An additional enhanced response was observed from the treatment group that received a boost injection 30 days after the prime dose. This group exhibited a 100% contraceptive effect (Miller et al. 2006) . These results clearly indicate that the rmGnRH protein, in adequate concentrations, is sufficiently immunogenic to cause contraception.
DISCUSSION
The unique design of Talwar's multimeric GnRH gene sequence has allowed for the expression of a highly immunogenic recombinant GnRH (rmGnRH) protein in E. co/i. These multiple T-cell epitopes provide the enhanced immunogenicity needed to generate a cell-mediated and humeral immune response to the GnRFI peptide.
The studies performed at PSU incorporated the rmGnRH protein into an injectable emulsion with AdjuVac. The recombinant protein elicited an impressive anti-GnRH immune antibody response resulting in contraception in 3 of 5 gilts with a single injection, and 5 of 5 gilts with a dual injection. Scale-up production ofrmGnRH utilizing high protein yield expression E. co/i strains will generate increased protein yields at a reasonable cost, thus making oral and large-scale use more feasible.
Inducing a strong systemic immune response with vaccination in feral swine, B. suis strain 353-1, a naturally rough mutant, would serve as a vector for the recombinant expression of rmGnRH. Utilized as an oral delivery system, a humeral and cell-mediated immune response to the bacterial strain itself would generate protective antibody production to virulent B. suis, as well as immunocontraceptive antibodies to endogenous GnRH, resulting in contraception.
